Conjugation of monoclonal antibodies to a synthetic peptide substrate for protein kinase

A method for labelling antibodies with 32P

B. M J Foxwell, H. A. Band, J. Long, W. A. Jeffery, D. Snook, P. E. Thorpe, G. Watson, P. J. Parker, A. A. Epenetos, A. M. Creighton

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

In recent years, radiolabelled monoclonal antibodies have been evaluated for their use in the diagnosis and treatment of neoplastic disease. One isotope which has not been assessed for antibody targeting is 32P, even though it has many favourable radiobiological characteristics and has been used clinically for the treatment of certain neoplastic disorders such as polycythaemia rubra vera. The main drawback so far in using 32P has been the absence of a general method for phosphorylating antibodies. We have now developed a novel process for the phosphorylation of immunoglobulins which is rapid, efficient and allows high specific activities to be achieved (>10 μCi μg-1). The technique involves the chemical conjugation of Kemptide, a synthetic heptapeptide substrate for kinases, to immunoglobulins. The antibody-Kemptide conjugate can then be phosphorylated using protein kinases and [32P]-γ-ATP. The procedure does not compromise the binding activity of the antibody. The 32P-labelled monoclonal antibodies were stable in human, mouse and rat plasmas in vitro, although they cleared from the bloodstream of mice with a β-phase half life of 2 days which is approximately two times faster than that of native antibody. The application of this phosphorylation technique should allow the therapeutic potential of targeted 32P to be assessed.

Original languageEnglish (US)
Pages (from-to)489-493
Number of pages5
JournalBritish Journal of Cancer
Volume57
Issue number5
StatePublished - 1988

Fingerprint

Cyclic AMP-Dependent Protein Kinases
kemptide
Monoclonal Antibodies
Peptides
Antibodies
Immunoglobulins
Phosphorylation
Polycythemia Vera
Isotopes
Protein Kinases
Half-Life
Phosphotransferases
Adenosine Triphosphate
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Foxwell, B. M. J., Band, H. A., Long, J., Jeffery, W. A., Snook, D., Thorpe, P. E., ... Creighton, A. M. (1988). Conjugation of monoclonal antibodies to a synthetic peptide substrate for protein kinase: A method for labelling antibodies with 32P. British Journal of Cancer, 57(5), 489-493.

Conjugation of monoclonal antibodies to a synthetic peptide substrate for protein kinase : A method for labelling antibodies with 32P. / Foxwell, B. M J; Band, H. A.; Long, J.; Jeffery, W. A.; Snook, D.; Thorpe, P. E.; Watson, G.; Parker, P. J.; Epenetos, A. A.; Creighton, A. M.

In: British Journal of Cancer, Vol. 57, No. 5, 1988, p. 489-493.

Research output: Contribution to journalArticle

Foxwell, BMJ, Band, HA, Long, J, Jeffery, WA, Snook, D, Thorpe, PE, Watson, G, Parker, PJ, Epenetos, AA & Creighton, AM 1988, 'Conjugation of monoclonal antibodies to a synthetic peptide substrate for protein kinase: A method for labelling antibodies with 32P', British Journal of Cancer, vol. 57, no. 5, pp. 489-493.
Foxwell, B. M J ; Band, H. A. ; Long, J. ; Jeffery, W. A. ; Snook, D. ; Thorpe, P. E. ; Watson, G. ; Parker, P. J. ; Epenetos, A. A. ; Creighton, A. M. / Conjugation of monoclonal antibodies to a synthetic peptide substrate for protein kinase : A method for labelling antibodies with 32P. In: British Journal of Cancer. 1988 ; Vol. 57, No. 5. pp. 489-493.
@article{f16a997b4d4f43c09a2c43089755cc6b,
title = "Conjugation of monoclonal antibodies to a synthetic peptide substrate for protein kinase: A method for labelling antibodies with 32P",
abstract = "In recent years, radiolabelled monoclonal antibodies have been evaluated for their use in the diagnosis and treatment of neoplastic disease. One isotope which has not been assessed for antibody targeting is 32P, even though it has many favourable radiobiological characteristics and has been used clinically for the treatment of certain neoplastic disorders such as polycythaemia rubra vera. The main drawback so far in using 32P has been the absence of a general method for phosphorylating antibodies. We have now developed a novel process for the phosphorylation of immunoglobulins which is rapid, efficient and allows high specific activities to be achieved (>10 μCi μg-1). The technique involves the chemical conjugation of Kemptide, a synthetic heptapeptide substrate for kinases, to immunoglobulins. The antibody-Kemptide conjugate can then be phosphorylated using protein kinases and [32P]-γ-ATP. The procedure does not compromise the binding activity of the antibody. The 32P-labelled monoclonal antibodies were stable in human, mouse and rat plasmas in vitro, although they cleared from the bloodstream of mice with a β-phase half life of 2 days which is approximately two times faster than that of native antibody. The application of this phosphorylation technique should allow the therapeutic potential of targeted 32P to be assessed.",
author = "Foxwell, {B. M J} and Band, {H. A.} and J. Long and Jeffery, {W. A.} and D. Snook and Thorpe, {P. E.} and G. Watson and Parker, {P. J.} and Epenetos, {A. A.} and Creighton, {A. M.}",
year = "1988",
language = "English (US)",
volume = "57",
pages = "489--493",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Conjugation of monoclonal antibodies to a synthetic peptide substrate for protein kinase

T2 - A method for labelling antibodies with 32P

AU - Foxwell, B. M J

AU - Band, H. A.

AU - Long, J.

AU - Jeffery, W. A.

AU - Snook, D.

AU - Thorpe, P. E.

AU - Watson, G.

AU - Parker, P. J.

AU - Epenetos, A. A.

AU - Creighton, A. M.

PY - 1988

Y1 - 1988

N2 - In recent years, radiolabelled monoclonal antibodies have been evaluated for their use in the diagnosis and treatment of neoplastic disease. One isotope which has not been assessed for antibody targeting is 32P, even though it has many favourable radiobiological characteristics and has been used clinically for the treatment of certain neoplastic disorders such as polycythaemia rubra vera. The main drawback so far in using 32P has been the absence of a general method for phosphorylating antibodies. We have now developed a novel process for the phosphorylation of immunoglobulins which is rapid, efficient and allows high specific activities to be achieved (>10 μCi μg-1). The technique involves the chemical conjugation of Kemptide, a synthetic heptapeptide substrate for kinases, to immunoglobulins. The antibody-Kemptide conjugate can then be phosphorylated using protein kinases and [32P]-γ-ATP. The procedure does not compromise the binding activity of the antibody. The 32P-labelled monoclonal antibodies were stable in human, mouse and rat plasmas in vitro, although they cleared from the bloodstream of mice with a β-phase half life of 2 days which is approximately two times faster than that of native antibody. The application of this phosphorylation technique should allow the therapeutic potential of targeted 32P to be assessed.

AB - In recent years, radiolabelled monoclonal antibodies have been evaluated for their use in the diagnosis and treatment of neoplastic disease. One isotope which has not been assessed for antibody targeting is 32P, even though it has many favourable radiobiological characteristics and has been used clinically for the treatment of certain neoplastic disorders such as polycythaemia rubra vera. The main drawback so far in using 32P has been the absence of a general method for phosphorylating antibodies. We have now developed a novel process for the phosphorylation of immunoglobulins which is rapid, efficient and allows high specific activities to be achieved (>10 μCi μg-1). The technique involves the chemical conjugation of Kemptide, a synthetic heptapeptide substrate for kinases, to immunoglobulins. The antibody-Kemptide conjugate can then be phosphorylated using protein kinases and [32P]-γ-ATP. The procedure does not compromise the binding activity of the antibody. The 32P-labelled monoclonal antibodies were stable in human, mouse and rat plasmas in vitro, although they cleared from the bloodstream of mice with a β-phase half life of 2 days which is approximately two times faster than that of native antibody. The application of this phosphorylation technique should allow the therapeutic potential of targeted 32P to be assessed.

UR - http://www.scopus.com/inward/record.url?scp=0023885024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023885024&partnerID=8YFLogxK

M3 - Article

VL - 57

SP - 489

EP - 493

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 5

ER -